SCHEMBL910340

SCHEMBL910340

CC(=O)c1cc(C)cc2c(=O)cc(-c3cccnc3)oc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 3/20 0.54
▸ CYP1A2 P05177 3/20 0.54
▸ CYP1B1 Q16678 3/20 0.54
▸ KDM4E B2RXH2 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ PRKDC P78527 1/20 0.53
▸ CSNK2A2 P19784 8/20 0.48
▸ CSNK2B P67870 8/20 0.48
▸ CSNK2A1 P68400 8/20 0.48
▸ CYSLTR1 Q9Y271 1/20 0.45
▸ MAOA P21397 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ PIK3CD O00329 1/20 0.43
▸ PIK3CA P42336 1/20 0.43
▸ PIK3CB P42338 1/20 0.43
▸ PIK3CG P48736 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ PPARG P37231 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL909776 0.85 PIK3CD (0.54) CYP1A1CYP1A2CYP1B1CSNK2A2CSNK2B
SCHEMBL24913400 0.85 CSNK2A2 (0.55) CYP1A1CYP1A2CYP1B1KDM4EKMT2A
SCHEMBL30742524 0.81 KCNA3 (0.43) KDM4EKMT2ACSNK2A2CSNK2BCSNK2A1
SCHEMBL26662329 0.81 KCNA3 (0.43) KDM4EKMT2ACSNK2A2CSNK2BCSNK2A1
SCHEMBL27129875 0.78 PIK3CA (0.60) CYP1A1CYP1A2CYP1B1KDM4EKMT2A
SCHEMBL27008382 0.78 PIK3CA (0.60) CYP1A1CYP1A2CYP1B1KDM4EKMT2A
SCHEMBL910042 0.78 CYP1A1 (0.54) CYP1A1CYP1A2CYP1B1CSNK2A2CSNK2B
SCHEMBL27129922 0.78 PIK3CD (0.54) CYP1A1CYP1A2CYP1B1KDM4EKMT2A
SCHEMBL26884771 0.78 PIK3CD (0.54) CYP1A1CYP1A2CYP1B1KDM4EKMT2A
SCHEMBL30928765 0.77 BRD4 (0.44) CYP1A1CYP1A2CYP1B1CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872011-B2 Inhibition of phosphoinositide 3-kinase β ASTRAZENECA AB (SE) 2011-01-18 — — US disclosed
US-7598377-B2 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy ASTRAZENECA AB (SE) 2009-10-06 — — US disclosed
US-20080319021-A1 Inhibition Of Phosphoinositide 3-Kinase Beta KINACIA PTY. LTD. (AU) 2008-12-25 — — US disclosed
US-20060276470-A1 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy ASTRAZENECA AB (SE) 2006-12-07 — — US disclosed
EP-1537102-A1 INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA Kinacia Pty Ltd. (AU) 2005-06-08 — — EP disclosed
WO-2004016607-A1 INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA KINACIA PTY LTD. (AU) 2004-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319021-A1 Inhibition Of Phosphoinositide 3-Kinase Beta PI4KB, PI4KA, PI4K2B CYP1A1 4600/4885CYP1A2 4298/4885CYP1B1 3709/4885
US-20060276470-A1 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy PI4KA, PI4KB, PI4K2B CYP1A1 3424/4885CYP1A2 3026/4885CYP1B1 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback